Gentian Diagnostics ASA
Develops and markets in vitro diagnostic reagents for human and veterinary use.
GENT | OL
Overview
Corporate Details
- ISIN(s):
- NO0010748866
- LEI:
- 5967007LIEEXZXHNM861
- Country:
- Norway
- Address:
- Bjørnåsveien 5, 1596 Moss
- Website:
- https://www.gentian.com/
- Sector:
- Manufacturing
Description
Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-10-24 06:30 |
Gentian Diagnostics: Invitation to presentation of third quarter results
|
English | 771 bytes | ||
| 2024-10-10 07:25 |
Gentian Diagnostics announces the death of its founder Dr. Erling Sundrehagen
|
English | 102.4 KB | ||
| 2024-10-10 07:25 |
Gentian Diagnostics announces the death of its founder Dr. Erling Sundrehagen
|
English | 2.0 KB | ||
| 2024-09-30 13:07 |
Gentian Diagnostics ASA awarded European patent for novel NT-proBNP reference m…
|
English | 2.6 KB | ||
| 2024-08-29 06:00 |
Gentian Diagnostics: Second quarter 2024 report
|
English | 831.6 KB | ||
| 2024-08-29 06:00 |
Gentian Diagnostics: Second quarter 2024 report
|
English | 1.8 MB | ||
| 2024-08-29 06:00 |
Gentian Diagnostics: Second quarter 2024 report
|
English | 2.7 KB | ||
| 2024-08-22 08:00 |
Gentian Diagnostics: Invitation to presentation of second quarter results
|
English | 772 bytes | ||
| 2024-08-05 09:20 |
Appointment of Chief Technology Officer
|
English | 2.4 KB | ||
| 2024-07-31 06:30 |
Gentian Diagnostics presents its NT-proBNP prototype at the ADLM
|
English | 255.9 KB | ||
| 2024-07-31 06:30 |
Gentian Diagnostics presents its NT-proBNP prototype at the ADLM
|
English | 3.0 KB | ||
| 2024-07-22 12:21 |
Matti Heinonen (Arvela) appointed as CEO of Gentian Diagnostics
|
English | 133.9 KB | ||
| 2024-07-22 12:21 |
Matti Heinonen (Arvela) appointed as CEO of Gentian Diagnostics
|
English | 3.1 KB | ||
| 2024-06-28 09:02 |
Groundbreaking assay development for measuring total NT-proBNP levels
|
English | 3.6 KB | ||
| 2024-06-28 06:34 |
Gentian Diagnostics: NT-proBNP successful completion of optimisation phase
|
English | 3.4 KB |
Automate Your Workflow. Get a real-time feed of all Gentian Diagnostics ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gentian Diagnostics ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gentian Diagnostics ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
